News & Media
COVID-19 press releases

COVID-19 press releases

After assessing safety and immunogenicity in phase 1/2 clinical trials, NVX-CoV2373 is currently in two pivotal phase 3 studies to evaluate vaccine efficacy, safety and immunogenicity. 

NVX-CoV2373 clinical trials have enrolled more than 30,000 volunteers around the globe. Learn more about our clinical trial enrollment and progress toward diversity demographics.

Feb 13, 2023
COVID-19

U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

Read full article
Jan 27, 2023
Statement
COVID-19

Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting

Read full article
Jan 18, 2023
COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

Read full article
Dec 30, 2022
COVID-19,Seasonal influenza

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Read full article
Dec 16, 2022
Statement
COVID-19
Global health

German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster

Read full article
Dec 7, 2022
COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents

Read full article
Nov 29, 2022
COVID-19

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

Read full article
Nov 23, 2022
Statement
COVID-19

Termination of COVID-19 Vaccine Purchase Agreement with Gavi

Read full article
Nov 18, 2022
COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Read full article
Nov 9, 2022
COVID-19

Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults

Read full article
Highlights

Visit our global authorization website

Learn more

Our commitment to equitable access and transparency

Learn more

COVID-19 vaccine clinical trial

PREVENT-19 phase 3 data fact sheet
Estudio en fase 3 PREVENT-19 hoja de datos

Announcement of UK and South Africa trial results

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

Learn more

PREVENT-19 fact sheet

Background information on PREVENT-19, Novavax pivotal phase 3 trial

Download
Showper page